Key Considerations When Developing a DOAC – Part 3

DOAC
Share this:
Print Friendly, PDF & Email

The currently approved direct oral anti-coagulants have proven to be safe and efficacious in prevention of stroke in patients with AF. However, the choice of DOAC is influenced by several factors including specific patient characteristics (renal function etc.), preference of OD versus BID, physicians comfort with the drug and the cost of drug to the patient.

While there are no head-to-head clinical trials conducted to-date between the DOACs, several observational studies have been performed to understand physicians’ and patients’ perspective about these direct oral anticoagulants.


Click here to download

Related Post

Preeti Parikh
Preeti Parikh
Preeti has been with RAS since its inception in 2014. She has worked on several projects involving strategy development, competitive intelligence and market analysis. She is passionate about data which she combines with her natural knack for visualisation and creating engaging content. Preeti began her career with a Masters Degree in Biotechnology from University of Abertay

Leave a Reply

Your email address will not be published. Required fields are marked *

*